Patients with coronary artery disease (CAD) often experience chest pain due to gastroesophageal reflux and aspirin-related gastrointestinal issues, which can be relieved by proton pump inhibitors (PPIs) like omeprazole.
A study involving 48 CAD patients without significant gastrointestinal symptoms examined the effects of omeprazole versus a placebo using a double-blind, cross-over design, assessing health-related quality of life using the SF-36 questionnaire.
Results showed that omeprazole significantly improved overall health-related quality of life scores, including physical and mental health aspects, compared to placebo, indicating its benefits for CAD patients experiencing non-severe gastrointestinal issues.